Metagenomics enables parallel detection of 176 clinically relevant targets from faecal samples
The faecal mNGS assay performed competitively with existing diagnostic techniques while substantially expanding actionable detection in a single assay. These results support stool mNGS as a high-yield second-line or syndromic test for gastrointestinal infection, enabling improved recognition of rare pathogens, co-infections, and resistance determinants.
Authors
- Nicola Angel
- Samantha MacDonald
- Lutz Krause (ORCID: https://orcid.org/0000-0003-3806-0845)
- Tyson Gene W.
- Michael C. Wehrhahn (ORCID: https://orcid.org/0000-0003-1325-669X)
- Alena L. Pribyl (ORCID: https://orcid.org/0000-0002-7625-5259)
- Andrew N. Ginn
- Donovan H. Parks (ORCID: https://orcid.org/0000-0001-6662-9010)
- R.B. Newell (ORCID: https://orcid.org/0000-0002-1300-6116)
- Paul M. Griffin (ORCID: https://orcid.org/0000-0002-0206-4775)
- Areej Alsheikh-Hussain (ORCID: https://orcid.org/0000-0002-9681-8565)
- Sarah Shah
- Tristan Wimpenny
- David L. A. Wood
- Jim P. Newcombe
- Philip Hugenholtz
- Kate L. Bowerman
- Peter Evans
- Nadia E. Arias Guzman
- Liang Fang
Institutions
- Translational Research Institute (AU)
- Mater Health Services (AU)
- Queensland University of Technology (AU)
- The University of Queensland (AU)
- Ecogenomics (Japan) (JP)
- Douglass Hanly Moir Pathology (AU)
Publication Details
- Journal
- Frontiers in Cellular and Infection Microbiology
- Published
- 2026-02-23
- DOI
- https://doi.org/10.3389/fcimb.2026.1759322
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.00